Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 16/20 | 0.52 |
| ▸ | CA1 | P00915 | 15/20 | 0.52 |
| ▸ | MMP1 | P03956 | 4/20 | 0.52 |
| ▸ | MMP2 | P08253 | 4/20 | 0.52 |
| ▸ | MMP9 | P14780 | 4/20 | 0.52 |
| ▸ | MMP8 | P22894 | 4/20 | 0.52 |
| ▸ | MMP13 | P45452 | 4/20 | 0.52 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1496678 | 0.97 | CA2 (0.54) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL5960728 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL544823 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1831160 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Lithium Ion SCHEMBL21802717 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL1835423 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Silver SCHEMBL2906769 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL20583880 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| SCHEMBL545689 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 | |
| Lithium Ion SCHEMBL443931 | 0.94 | CA2 (0.52) | CA2CA1MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7906667-B2 | Method for producing optically active alcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20100234629-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-1982973-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234629-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ALCOHOL COMPOUND | ADH1A, ADH1C, ADH5 | CA2 357/4885CA1 429/4885MMP1 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.